Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin lambda-like polypeptide 1 pseudogene (ENSEMBL: ENSG00000234353) is a genetic segment homologous to the functional IGLL1 gene, a member of the immunoglobulin gene superfamily involved in early B-cell development[1][6]. Pseudogenes are categorized by their lack of protein-coding capacity, often due to disabling mutations, lack of promoters, or incomplete gene structure[2][5][8]. This specific pseudogene does not encode a functional protein and is not involved in known physiological or pathological processes, nor is it considered a druggable therapeutic target. Pseudogenes may occasionally be transcribed, but the immunoglobulin lambda-like polypeptide 1 pseudogene has no well-established function or disease relevance[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin lambda-like polypeptide 1 pseudogene.